Kinaxo and Bayer Vital collaborate in cancer biomarker
21 October 2009
Kinaxo Biotechnologies GmbH and Bayer Vital GmbH have
announced that they will enter into collaboration to develop cancer
Kinaxo will apply its quantitative phosphoproteomics technology
PhosphoScout for the identification of novel biomarkers in a clinical
trial conducted by Bayer Vital.
KINAXO’s phosphoproteomics platform allows annotation and
quantification of regulated phosphorylation sites.
Since the majority of targeted compounds used as anti-cancer drugs
influence cellular signal transduction pathways, analysis of
phosphorylation patterns in relation to drug administration reveals a
compound’s molecular mode of action. Characteristic phosphorylation
sites predicting response to treatment, resistance mechanism or
synergistic effects can hereby be identified as biomarkers which allow
for personalized treatment plans.
Accompanying a clinical trial for the multi-kinase inhibitor Nexavar
in Acute Myeloid Leukemia (AML), KINAXO will apply its phosphoproteomics
technology to reveal the drug’s influence on cellular phosphorylation
patterns and to search for novel predictive biomarkers.
Nexavar is already approved for the treatment of hepatocellular (HCC)
and renal cell carcinoma (RCC) and shows promising effects in several
other indications, amongst them AML, the most common type of leukemia in
Despite considerable efforts over the last decades, therapeutic
outcome in AML therapy has improved only modestly and remains dismal,
with a high number of patients being non-responsive to standard
treatment or recurrent.
Application of KINAXO’s phosphoproteomics technology could thus turn
out to be a valuable tool to discover predictive biomarkers that
foretell therapeutic outcome in patients.
Furthermore, quantitative phosphoproteomics will be applied to
investigate the molecular efficiency of potential combination therapies
in which Nexavar will be administered together with other targeted drugs
to effectively fight cancer. In turn, individualized therapeutic
strategies could then improve overall treatment outcome for malignant
diseases, such as AML.
Dr. Erich Enghofer, Head of the Business Unit Oncology, said, “New
treatment options, such as Nexavar, are responsible for the progress
which has been achieved in recent years in the fight against cancer. Yet
we still have a long way to go until a truly personalized medicine,
based on validated biomarkers, will become a reality.
"That is the reason why we need to further investigate new diagnostic
and treatment approaches. The co-operation between the business unit
oncology at Bayer Vital in Leverkusen and Kinaxo Biotechnologies in
Martinsried with Germany as the prime research site gives us a unique
chance to substantially contribute to the improvement of cancer
"Both partners aim at investigating innovative technologies (such as
phosphoproteomics) and targeted therapies (such as kinase inhibitors)
which — in conjunction — should allow more effective cancer treatments
and, thus, provide more hope to cancer patients.”